Skip to main content

DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS BASADAS EN EL PERFIL GENETICO/MOLECULAR DEL CANCER DE PULMON.

BES-2015-072204

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero, Octavio A.|||0000-0003-0229-6530
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Andrades, Álvaro
  • Trastulli, Deborah|||0000-0003-2407-3290
  • Pros, Eva|||0000-0002-2366-7866
  • Setien, Fernando|||0000-0002-4061-4635
  • Verdura, Sara|||0000-0001-8980-0423
  • Farré, Lourdes|||0000-0002-3168-1940
  • Martín-Tejera, Juan F.
  • Llabata, Paula|||0000-0001-7733-6475
  • Oaknin, Ana|||0000-0002-3592-7194
  • Saigí, Maria|||0000-0001-5815-5388
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Medina, Pedro P.
  • Vidal, August|||0000-0001-5727-2099
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Navajas-Chocarro, Pablo
  • Saigí, Maria|||0000-0001-5815-5388
  • Ferrero-Andres, Ana
  • Morillas, Juan M.
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Mate, José L.
  • Munoz-Marmol, Ana M.
  • Romero, Octavio A.|||0000-0003-0229-6530
  • Blecua, Pedro|||0000-0002-1012-0300
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M.|||0000-0003-4490-6093
  • Pros, Eva|||0000-0002-2366-7866
  • Llabata, Paula|||0000-0001-7733-6475
  • Torres-Diz, Manuel
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study the cell-intrinsic response of lung cancer (LC) to interferon-γ (IFNγ), a cytokine that promotes immunoresponse and modulates programmed death-ligand 1 (PD-L1) levels. We report complete refractoriness to IFNγ in a subset of LCs as a result of JAK2 or IFNGR1 inactivation. A submaximal response affects another subset that shows constitutive low levels of IFNγ-stimulated genes (IγSGs) coupled with decreased H3K27ac (histone 3 acetylation at lysine 27) deposition and promoter hypermethylation and reduced IFN regulatory factor 1 (IRF1) recruitment to the DNA on IFNγ stimulation. Most of these are neuroendocrine small cell LCs (SCLCs) with oncogenic MYC/MYCL1/MYCN. The oncogenic activation of MYC in SCLC cells downregulates JAK2 and impairs IγSGs stimulation by IFNγ. MYC amplification tends to associate with a worse response to anti-PD1/L1 therapies. Hence alterations affecting the JAK/STAT pathway and MYC activation prevent stimulation by IFNγ and may predict anti-PD1/L1 efficacy in LC.